Published in Vaccine Weekly, August 22nd, 2001
The decision is based on discussions with representatives from the Biologics and Genetic Therapies Directorate of Health Canada's Health Products and Food Branch (Directorate) following the presentation of a summary of Phase II trial results. CancerVax anticipates completing the submission by the third quarter of 2002.
CancerVax presented a summary of the extensive Phase II data on the use of its therapeutic vaccine in patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly